Meeting Banner
Abstract #1165

Validation of T2 mapping for treatment response monitoring in longitudinal multi-center clinical trials

Petra J van Houdt 1 , Harsh K Agarwal 2,3 , Laurens B van Buuren 1 , Marko Ivancevic 4 , Sren Haack 5 , Jesper Folsted Kallehauge 6 , Peter L Choyke 3 , and Uulke A van der Heide 1

1 Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands, 2 Philips Research NA, Briarcliff Manor, MD, United States, 3 National Cancer Institute, National Institutes of Health, Bethesda, NY, United States, 4 Philips Healthcare, Best, Netherlands, 5 Clinical Engineering, Aarhus University Hospital, Aarhus, Denmark, 6 Medical Physics, Aarhus University Hospital, Aarhus, Denmark

T2 is proposed as a biomarker for response monitoring of patients with prostate cancer treated with radiotherapy. A key requirement in multi-center longitudinal studies is good reproducibility over multiple visits. The purpose of this study was to establish the inter- and intra-center reproducibility of T2 maps. Phantom measurements were performed on three platforms, showing that the differences in T2 values within and between platforms were smaller than 5%. Average difference in T2 values of volunteers between two visits was -1.5 +/- 9.5%. This work demonstrates that T2 mapping is suitable for use in multi-center, longitudinal trials in prostate cancer patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here